Ordesekimab Biosimilar - Research Grade

Human

IL15

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P40933

3600

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-IL-15 antibody ordesekimab (also known in the literature as AMG 714 / PRV-015), supplied strictly for research use only. It is built as a human IgG1/kappa molecule directed against human interleukin-15 (IL15, UniProt P40933), reproducing the target specificity of the originator drug without being the clinical product and without any conjugate or label. It is not intended for human or veterinary use. The material is well suited to in-vitro and preclinical research where a defined IL-15-neutralizing binder is needed, including cytokine-blocking assays, competition and epitope studies, positive controls for anti-IL-15 detection workflows, screening of biosimilar candidates, and as a reference reagent in ADCC/effector-function or engineering programs. It is manufactured to research-grade low-endotoxin specifications (typically less than 1 EU/mg, with ultra-low-endotoxin options under 0.5 EU/mg) and is available in bulk milligram-to-gram quantities, making it appropriate for scale-dependent and endotoxin-sensitive experiments such as primary immune-cell cultures. Interleukin-15 (IL15, UniProt P40933) is a small four-helix-bundle cytokine of the common gamma-chain family, structurally related to IL-2. It signals through a heterotrimeric receptor comprising the private high-affinity IL-15 receptor alpha (IL-15Ralpha), the shared IL-2/IL-15 receptor beta (CD122), and the common gamma chain (CD132), activating JAK1/JAK3 and STAT5. A hallmark of IL-15 biology is trans-presentation: IL-15Ralpha on antigen-presenting cells captures IL-15 and presents it in trans to CD122/CD132 on responding cells. IL-15 is essential for the development, survival, and homeostasis of natural killer cells, NKT cells, and CD8+ memory T cells, and it promotes their proliferation and cytotoxicity. Dysregulated IL-15 signaling is implicated in inflammatory and autoimmune conditions, including celiac disease and refractory forms, which motivated therapeutic IL-15 blockade.

Interleukin-15

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Ordesekimab biosimilar available in bulk or gram quantities?

A: Yes — the Ordesekimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Ordesekimab suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ordesekimab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Ordesekimab that binds IL15; for research use only (RUO).